Systemic factors associated with poor anatomical response to anti-VEGF therapy in patients with diabetic macular edema: evidence from a large clinical cohort - Top-Institutions - MDSpire

Systemic Influences Linked to Suboptimal Anatomical Outcomes Following Anti-VEGF Treatment in Diabetic Macular Edema Patients: Insights from a Large Clinical Cohort

  • By

  • Xinru Jia

  • Yan Shi

  • Mengxiang He

  • Dongwei Yao

  • Chengfei Lin

  • July 21, 2026

Share

Top Institutions in Ophthalmology

Brief introduction explaining scope and methodology.

  • #1

    Diabetic Retinopathy Clinical Research (DRCR) Network
    Diabetic Retinopathy Clinical Research (DRCR) Network

    N/A, N/A

    Key Differentiators

    • Ophthalmology

  • #2

    Ophthalmic Consultants of Boston
    Ophthalmic Consultants of Boston

    Boston, MA

    Key Differentiators

    • Ophthalmology

  • #3

    Center for Eye Research and Education
    Center for Eye Research and Education

    N/A, N/A

    Key Differentiators

    • Ophthalmology

  • #4

    Wilmer Eye Institute, Johns Hopkins School of Medicine
    Wilmer Eye Institute, Johns Hopkins School of Medicine

    Baltimore, MD

    Key Differentiators

    • Ophthalmology

  • #5

    Stanford University
    Stanford University

    Stanford, CA

    Key Differentiators

    • Ophthalmology

Original Source(s)

Systemic factors associated with poor anatomical response to anti-VEGF therapy in patients with diabetic macular edema: evidence from a large clinical cohort

  • by Xinru Jia, Yan Shi, Mengxiang He, Dongwei Yao, Chengfei Lin

  • July 21, 2026

Related Content

GLP-1 RAs Associated With Small ION Risk Increase

In an observational US target trial emulation, glucagon-like peptide-1 receptor agonist initiation was associated with about 3 to 4 more ischemic optic neuropathy cases per 10,000 patients over 18 months than two comparator drug classes.

Diabetic Retinal Disease Rates Narrow by Diabetes Type

US claims data showed rising prevalence of diabetic retinal disease in type 1 and type 2 diabetes, while incidence declined in type 1 diabetes and moved closer to type 2 rates by 2022.

GLP-1 Eye Effects Raise Questions

Authors describe both potential retinal benefits and possible rare optic nerve risks, while emphasizing that long-term ocular safety data remain limited as use expands.